Pulmonary embolism after total joint arthroplasty: cost and effectiveness of four treatment modalities.

Raphael IJ, McKenzie JC, Zmistowski B, Brown DB, Parvizi J, Austin MS
J Arthroplasty. 2014 29 (5): 933-7

PMID: 24269095 · DOI:10.1016/j.arth.2013.09.033

Pulmonary embolism (PE) treatment relies on therapeutic anticoagulation and may be associated with severe complications. Inferior vena cava filters (IVCFs) are used as an alternative/adjunct to anticoagulation. In this study we evaluate 4 treatment protocols for clinical efficacy and cost. We reviewed over 27,000 total joint arthroplasty (TJA) patients. We retrospectively identified 294 patients with a documented, symptomatic PE within 90 days of surgery. All patients were treated with warfarin postoperatively. In addition, for the acute management, patients were divided into four treatment groups: (1) IVCF only, (2) IVCF with heparin, (3) heparin only and (4) no treatment. Complication rates, hospital stay and PE recurrence are reported. Among patients who received warfarin, IVCF was associated with fewer complications and lower overall hospital costs compared to the use of heparin for the treatment of PE after TJA.

© 2014.

MeSH Terms (15)

Aged Aged, 80 and over Anticoagulants Arthroplasty, Replacement Costs and Cost Analysis Female Heparin Humans Male Middle Aged Pulmonary Embolism Retrospective Studies Treatment Outcome Vena Cava Filters Warfarin

Connections (1)

This publication is referenced by other Labnodes entities: